Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.

Seminars in thrombosis and hemostasis - 1 Jun 2006

Kiladjian Jean-Jacques, Rain Jean-Didier, Bernard Jean-Francois, Briere Jean, Chomienne Christine, Fenaux Pierre

Abstract excerpt

Despite recent discoveries made in myeloproliferative disorders other than chronic myelogenous leukemia, which it is hoped will result in earlier diagnosis, and better evaluation and management of patients, hematological evolution to myelofibrosis, acute leukemia, and myelodysplastic syndromes (AL/MDS) remain major causes of long-term mortality in polycythemia vera (PV) and essential thrombocythemia (ET)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to Hydroxyurea

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Leukemia

Share to Myelodysplastic Syndromes

Share to Polycythemia Vera

Share to Randomized Controlled Trials as Topic

Share to Thrombocythemia, Essential

Source

Identifiers

PMID: 16810617
DOI: 10.1055/s-2006-942762

Genes

JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.PMID 16810617Read ↗

Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

How I treat polycythemia vera.Semantic proximity Read ↗

Hydroxyurea: An Old Drug in Need of New Clinical Trials in Myeloproliferative NeoplasmsSemantic proximity Read ↗

Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC projectSemantic proximity Read ↗

The treatment of polycythaemia vera: an update in the JAK2 era.Semantic proximity Read ↗

ASXL1 mutations, previous vascular complications and age at diagnosis predict survival in 85 WHO-defined polycythaemia vera patients.Semantic proximity Read ↗

JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosisSemantic proximity Read ↗

Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?Semantic proximity Read ↗

Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses.Semantic proximity Read ↗

A real-world analysis of polycythemia vera at two comprehensive cancer centers in Cali, Colombia.Semantic proximity Read ↗

Life, genes, and death in Ph- MPNs.Semantic proximity Read ↗

Comment on: JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.